Ролиноз 10 мг/мл 20 мл капли для приема внутрь

Country: Kyrgyzstan

Language: Russian

Source: Правительства Кыргызской Республики (Департамент лекарственного обеспечения и медицинской техники)

Active ingredient:

Цетиризин

Available from:

Ротафарм Илачлары Лимитед Ширкети (Ротафарм Илачлары Лимитед Ширкети)

ATC code:

R06AE07

INN (International Name):

Cetirizine

Dosage:

10 мг/мл 20 мл

Pharmaceutical form:

капли для приема внутрь

Units in package:

№1

Prescription type:

без рецепта

Manufactured by:

Уорлд Медицин Илач Сан. ве Тидж. А.Ш. (Турция)

Therapeutic area:

Антигистаминное средство

Product summary:

ПЖВЛС: нет

Authorization date:

2018-05-25

Summary of Product characteristics

?
I
I
E
I
YTBEPXAAIo
llepnsrfi
3aMecrrrreJrb
Ar{percTopa
{enapramesra
.nercapcrBeHH
oro
o6ecueqenr{ff
rr MeAlrunncxofi
TexHrr
Muuncrepctna
sApasoo
Krrprrr:ucqfi
flyfiruena.luee
H.K.
u@,
A'n4
I
NHCTPYKIII,Ifl
tIO
MEAI,IUIIHCKOMY
TIPI,IMEHBHI,IIO
JIEKAPCTBEHHOTO
CPEACTBA
POJIIIHO3
ROLINOZ
2018
r :
caxapr4H
HaTpHs.
aueTaT
Tpr4rr4ApaT,
TOP|OBOE
HA3BAHI,IE
Porunos,
Rolinoz
ME}ITAYHAPOAHOE
HEIIATEHTOBAHHOE
HA3BAHIIE
I-{erupu:un,
Cetirizine
JIEKAPCTBEHHA-fl
@OPMA
Kanla
Anf,
npr4eMa
BHyrpb.
OIII,ICAHITE
llpo:pauuax
6ecqnerua.a
xs4AKocrb.
COCTAB
1 nan
npenapara
coAeplrr4T
A
rcmue
u
o
e 6
e
ul
e
c
m
s
o
:
rlerlrpr4
3
r{Ha
Ar,rrr{ApoxnoprzA
1
0 rr,rr.
BcnoaoeamerbHbte
6eulecm6a.'
rJr4qepr,rH,
npo[aneHrJrr4KoJrb,
Merrrnnapaflirpoxcu6eH3oar,
rrpolr{Jrrrapafr4ApoKcr.r6en3oar,
Harphrfl
yKcycHar
KlrcnoTa
lren.flIlAfl.,
BOAa
OqUUeHHat.
OAPMAKO
TEPAIIEBTI,IIIE
CKA.fl
IPYIIIIA
AururracrarrallHHble
[penaparbr
cr,rcreMHoro
Aeficrnras.
flpousno4Hbre
rrr4fiepa3uHa.I_{erupz:nn.
Koa
ATX
R06AE07
@APMAK
OIO f I4IIECKI,IE
C
B
OITCTBA
@APMAKON14HAMNRA
Porunos
aHTI4fI{craMIaHnufi
npenapar
II
rroKoJreHr4r,
ceJrexTr{snHfi
6roxarop
nepraQepnuecKl4x
Ht-peuenropoB.
OKa^:rmae'r
aHTr,rfr4craMrrr{Hoe
14 rrporr,rtsoannepn4qecKoe
Aeficrsl{e'
Porunos
[peAorBpalqaer
pa3Br4Tue
v o6rerqaer
reqeHr4e
anneprr{ecrux
peaxquft.
o
Ka3brBaer
rrporr4Bo3yAHo
e u
aHTLr
gKccyAarr,rBHoe
4eft
crnu
e.
BrHser
Ha
paHHIoIo
craAI{Io
annepfuqecKax
peaKrlrzfi,
a
raxxe
yMeHbrrraer
Mr.rrparlr4ro
KJreroK
BOCIIaJIeHI4';
yfHeraer
BbIAeneHHe
MeAr.raropoB,
yqacrByrorl[x
e
nosAuefi
craliuu
anreprnqecxofi
pearquu.
Cuzxaer
npoHl4llaeMocrb
Kanr.rnnqpoB,
npeAynpe)KAaer
pa3Br.rrHe
oreKa
txanefi,
cHI'IMaer
crla3M
magxofi
MycKynarypbl,
ycrpaHrer
KoxHyro
peaKrlr4io
Ha
BBeAeHI'Ie
f[craMl4Ha,
cleqz$nqecKl'Ix
annepreHoB,
a raKxe
Ha
oxnaxlenrae
(npu
xolo4onofr
KpanI'IBHHIIe).
CuraNaer
fucraMIzH-I{HAyIiapoBaHHyIo
6poHxoxoucrpr4Krlurc
ttpz
6po"xnalrgofi
acTMe
JrefKofo
TeqeHu{.
llpn
[pI,IMeHeHLII{
B
peKOMeHAyeMbIx
Ao3ax
npaKTI4qeCKu
He
OKa3bIBaeT
ceAaTI{BHOfo'
aHTI4XOJILrHeprI4qecKoro
r4 aHTLrCepoTo